Diacetylmorphine versus methadone for the treatment of opioid addiction
- PMID: 19692689
- PMCID: PMC5127701
- DOI: 10.1056/NEJMoa0810635
Diacetylmorphine versus methadone for the treatment of opioid addiction
Abstract
Background: Studies in Europe have suggested that injectable diacetylmorphine, the active ingredient in heroin, can be an effective adjunctive treatment for chronic, relapsing opioid dependence.
Methods: In an open-label, phase 3, randomized, controlled trial in Canada, we compared injectable diacetylmorphine with oral methadone maintenance therapy in patients with opioid dependence that was refractory to treatment. Long-term users of injectable heroin who had not benefited from at least two previous attempts at treatment for addiction (including at least one methadone treatment) were randomly assigned to receive methadone (111 patients) or diacetylmorphine (115 patients). The primary outcomes, assessed at 12 months, were retention in addiction treatment or drug-free status and a reduction in illicit-drug use or other illegal activity according to the European Addiction Severity Index.
Results: The primary outcomes were determined in 95.2% of the participants. On the basis of an intention-to-treat analysis, the rate of retention in addiction treatment in the diacetylmorphine group was 87.8%, as compared with 54.1% in the methadone group (rate ratio for retention, 1.62; 95% confidence interval [CI], 1.35 to 1.95; P<0.001). The reduction in rates of illicit-drug use or other illegal activity was 67.0% in the diacetylmorphine group and 47.7% in the methadone group (rate ratio, 1.40; 95% CI, 1.11 to 1.77; P=0.004). The most common serious adverse events associated with diacetylmorphine injections were overdoses (in 10 patients) and seizures (in 6 patients).
Conclusions: Injectable diacetylmorphine was more effective than oral methadone. Because of a risk of overdoses and seizures, diacetylmorphine maintenance therapy should be delivered in settings where prompt medical intervention is available. (ClinicalTrials.gov number, NCT00175357.)
2009 Massachusetts Medical Society
Conflict of interest statement
Dr. Brissette reports receiving consulting and lecture fees from Schering-Plough. No other potential conflict of interest relevant to this article was reported.
Figures
Comment in
-
Heroin prescription and history.N Engl J Med. 2009 Aug 20;361(8):820-1. doi: 10.1056/NEJMe0904243. N Engl J Med. 2009. PMID: 19692694 No abstract available.
-
Diacetylmorphine versus methadone for opioid addiction.N Engl J Med. 2009 Nov 26;361(22):2193-4; author reply 2195. doi: 10.1056/NEJMc0908720. N Engl J Med. 2009. PMID: 19940306 No abstract available.
-
Diacetylmorphine versus methadone for opioid addiction.N Engl J Med. 2009 Nov 26;361(22):2194-5; author reply 2195. N Engl J Med. 2009. PMID: 19950413 No abstract available.
-
Diacetylmorphine versus methadone for opioid addiction.N Engl J Med. 2009 Nov 26;361(22):2194; author reply 2195. N Engl J Med. 2009. PMID: 19950414 No abstract available.
-
Injectable diacetylmorphine is more effective than oral methadone in the treatment of chronic relapsing opioid dependence.Evid Based Ment Health. 2010 Aug;13(3):80. doi: 10.1136/ebmh.13.3.80. Evid Based Ment Health. 2010. PMID: 20682820 No abstract available.
References
-
- Cami J, Farre M. Drug addiction. N Engl J Med. 2003;349:975–86. - PubMed
-
- World drug report 2008. Vienna: United Nations Office on Drugs and Crime; 2008.
-
- Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health. 2006;120:320–8. - PubMed
-
- Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;2:CD002209. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical